Key result
Routine anticoagulant prophylaxis for venous thromboembolism cannot currently be recommended for most ambulatory patients with cancer due to a lack of clinical trials.
Why the study?
Does anticoagulant prophylaxis prevent venous thromboembolism in ambulatory patients with cancer?
Does anticoagulant prophylaxis prevent venous thromboembolism in ambulatory patients with cancer?
Current evidence is insufficient to recommend routine pharmacologic prophylaxis for venous thromboembolism in most ambulatory cancer patients, highlighting the need for further research to identify high-risk populations.
Answers are grounded in this paper and cite their sources.
Does not support routine prophylaxis in ambulatory cancer patients; leaves open targeted trials in high-risk subgroups.
Cancer patients with solid tumors or hematologic malignancies receive most of their cancer treatment as outpatients. Thromboembolism, when it occurs, complicates the clinical care of these patients because of the associated morbidity and the need for anticoagulant treatment. It would seem that prevention of venous thromboembolism in these patients would be worthwhile. However, to date there are relatively few trials of anticoagulant prophylaxis in ambulatory patients with cancer and it is not possible to recommend prophylaxis for most patients. Research is needed to better define a population at high enough risk to warrant pharmacologic prophylaxis and to develop new antithrombotic agents for this indication.
No takes yet. Share an insight, caveat, or question.
Rana et al. (2009) conducted a review in Cancer (solid tumors or hematologic malignancies) with risk of thromboembolism. Anticoagulant prophylaxis was evaluated on Venous thromboembolism. Routine anticoagulant prophylaxis for venous thromboembolism cannot currently be recommended for most ambulatory patients with cancer due to a lack of clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: